Jefferies initiated coverage on Disc Medicine with a new price target
$IRON
Biotechnology: Pharmaceutical Preparations
Health Care
Jefferies initiated coverage of Disc Medicine with a rating of Buy and set a new price target of $89.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/4/2024 | $66.00 → $110.00 | Outperform → Strong Buy | Raymond James |
| 10/23/2024 | $89.00 | Buy | Jefferies |
| 10/16/2024 | Sector Outperform | Scotiabank | |
| 8/22/2024 | $75.00 | Overweight | Wells Fargo |
| 4/1/2024 | $40.00 | Strong Buy → Outperform | Raymond James |
| 12/19/2023 | $56.00 → $65.00 | Overweight → Equal-Weight | Morgan Stanley |
| 6/9/2023 | $50.00 → $75.00 | Outperform → Strong Buy | Raymond James |
| 6/7/2023 | $55.00 | Buy | H.C. Wainwright |
Alignment with the FDA across all proposed study parameters, providing a clear development path to registrationAgreement on proposed primary endpoint of average monthly time in sunlight during the last month following a 6-month treatment periodPotential for accelerated approval based on existing data and utilizing reduction of PPIX as a surrogate endpointPlan to initiate APOLLO trial, a 6-month study of a 60 mg dose of bitopertin in EPP and XLP patients ages 12+ by mid-2025Management will host a conference call on Monday, November 4 at 8:00 am EST WATERTOWN, Mass., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on th
WATERTOWN, Mass., Nov. 01, 2024 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, will host a conference call to discuss feedback received from its end-of-Phase 2 (EOP2) meeting with the U.S. Food and Drug Administration (FDA). The conference call will be held on Monday, November 4, at 8:00 am EST. Conference Call Information Please register for the event on the Events and Presentations page of Disc's website at https://ir.discmedicine.com/. About Bitopertin Bitopertin is an investigational, clinical-s
WATERTOWN, Mass., Oct. 25, 2024 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today presented positive additional data from an ongoing Phase 1b study of DISC-0974 in patients with non-dialysis-dependent chronic kidney disease (NDD-CKD) and anemia, including results from the 40 mg and 60 mg single ascending dose (SAD) cohorts. The data presented at the 2024 American Society of Nephrology (ASN) Kidney Week in San Diego, CA demonstrated that a single dose of DISC-0974 results in sustained suppression of h
Raymond James upgraded Disc Medicine from Outperform to Strong Buy and set a new price target of $110.00 from $66.00 previously
Jefferies initiated coverage of Disc Medicine with a rating of Buy and set a new price target of $89.00
Scotiabank initiated coverage of Disc Medicine with a rating of Sector Outperform
4 - Disc Medicine, Inc. (0001816736) (Issuer)
4 - Disc Medicine, Inc. (0001816736) (Issuer)
4 - Disc Medicine, Inc. (0001816736) (Issuer)
SC 13G - Disc Medicine, Inc. (0001816736) (Subject)
SC 13D/A - Disc Medicine, Inc. (0001816736) (Subject)
SC 13D/A - Disc Medicine, Inc. (0001816736) (Subject)
4 - Disc Medicine, Inc. (0001816736) (Issuer)
4 - Disc Medicine, Inc. (0001816736) (Issuer)
4 - Disc Medicine, Inc. (0001816736) (Issuer)
WATERTOWN, Mass., Oct. 23, 2024 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced the appointment of Rahul Rajan Kaushik, Ph.D. as the company's Chief Technical Officer. Dr. Kaushik is an experienced biotech executive with significant expertise in chemistry, manufacturing, and controls (CMC) leadership across technical development, manufacturing and supply chain oversight for products in multiple modalities and therapeutic areas. "Rahul's experience is an ideal fit for Disc as we evolve in
WATERTOWN, Mass., Sept. 19, 2024 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced the appointment of Steve Caffé, MD as the company's Chief Regulatory Officer. Dr. Caffé is an experienced biotech executive with significant expertise in global regulatory leadership across a wide range of therapeutic areas, including hematology, oncology, and rare diseases. "We are excited to welcome an executive as accomplished as Steve to Disc, where his depth of regulatory expertise and experience in glo
WATERTOWN, Mass., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced the appointment of Pamela Stephenson, MPH as the company's Chief Commercial Officer. Ms. Stephenson is an experienced biotech executive with significant expertise in commercial and strategic leadership, particularly in therapies for rare diseases, and will be responsible for all aspects of Disc's global commercialization strategy and execution. "We are delighted to welcome an accomplished leader such as Pam
HC Wainwright & Co. analyst Douglas Tsao reiterates Disc Medicine (NASDAQ:IRON) with a Buy and maintains $70 price target.
BMO Capital analyst Evan Seigerman reiterates Disc Medicine (NASDAQ:IRON) with a Outperform and raises the price target from $50 to $70.
U.S. stocks traded mixed toward the trading, with the Dow Jones index falling around 0.2% on Friday. The Dow traded down 0.24% to 38,554.69 while the NASDAQ rose 0.07% to 17,680.01. The S&P 500 also fell, dropping, 0.10% to 5,428.33. . Check This Out: Top 2 Materials Stocks That May Collapse This Quarter Leading and Lagging SectorsCommunication services shares jumped by 0.5% on Friday. In trading on Friday, industrials shares fell by 1.2%. Top Headline The total number of active U.S. oil rigs declined by four to 488 rigs this week, Baker Hughes Inc reported. Equities Trading UP
Alignment with the FDA across all proposed study parameters, providing a clear development path to registrationAgreement on proposed primary endpoint of average monthly time in sunlight during the last month following a 6-month treatment periodPotential for accelerated approval based on existing data and utilizing reduction of PPIX as a surrogate endpointPlan to initiate APOLLO trial, a 6-month study of a 60 mg dose of bitopertin in EPP and XLP patients ages 12+ by mid-2025Management will host a conference call on Monday, November 4 at 8:00 am EST WATERTOWN, Mass., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on th
WATERTOWN, Mass., Nov. 01, 2024 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, will host a conference call to discuss feedback received from its end-of-Phase 2 (EOP2) meeting with the U.S. Food and Drug Administration (FDA). The conference call will be held on Monday, November 4, at 8:00 am EST. Conference Call Information Please register for the event on the Events and Presentations page of Disc's website at https://ir.discmedicine.com/. About Bitopertin Bitopertin is an investigational, clinical-s
Met primary endpoint, demonstrating dose-dependent, statistically significant reductions in protoporphyrin IX (PPIX) compared to placebo in both 20 mg and 60 mg dose groupsImproved measures of light tolerance, including the key secondary endpoint, in both 20 mg and 60 mg dose groups, but did not meet statistical significance compared to placeboDose-dependent reductions in the rate of phototoxic reactions with pain, with statistical significance at the 60 mg dose group compared to placeboDose-dependent improvements in the Patient Global Impression of Change (PGIC), with statistical significance at the 60 mg dose group compared to placeboInvestor webcast at 8:30 am ET to discuss top-line data
8-K - Disc Medicine, Inc. (0001816736) (Filer)
144 - Disc Medicine, Inc. (0001816736) (Subject)
8-K - Disc Medicine, Inc. (0001816736) (Filer)